First-Ever Survival Bump in Relapsed Mesothelioma
email article Patients with progressive mesothelioma obtained a first-ever survival improvement with nivolumab (Opdivo) as second-line therapy, a randomized trial showed. Median overall survival (OS) increased by almost 40%, and the progression-free interval also improved significantly with the immune checkpoint inhibitor as compared with placebo. In particular, a significant clinical benefit was evidence in patients with epithelioid subtype, the predominant mesothelioma histology. PD-L1 expression status did not influence response to treatment, although only a third of patients tested ...
Source: medpagetoday.com